



**BIOCON GROUP**

**FACT SHEET**

**December - 2020**

<b>BIOCON LIMITED (CONSOLIDATED)</b>			
<b>PROFIT &amp; LOSS STATEMENT</b>			
(Rs. Crores)			
<b>Particulars</b>	<b>Q3'FY 21</b>	<b>Q3'FY 20</b>	<b>Variance %</b>
<b><u>INCOME</u></b>			
Generics	561	576	-3%
Biosimilars	769	693	11%
Novel Biologics	-	-	-
Research services	585	519	13%
Inter-segment	(63)	(71)	-11%
<b>Revenue from operations #</b>	<b>1,851</b>	<b>1,717</b>	<b>8%</b>
Other income	28	36	-22%
<b>TOTAL REVENUE</b>	<b>1,879</b>	<b>1,753</b>	<b>7%</b>
<b><u>EXPENDITURE</u></b>			
Material & Power costs	632	606	4%
Staff costs	411	342	20%
Research & Development expenses*	171	131	30%
Other expenses	239	193	24%
<b>Manufacturing, staff &amp; other expenses</b>	<b>1,452</b>	<b>1,273</b>	<b>14%</b>
<b>EBITDA</b>	<b>427</b>	<b>480</b>	<b>-11%</b>
Interest & Finance charges	5	18	-73%
Depreciation & Amortisation	186	144	29%
<b>PBT BEFORE EXCEPTIONAL ITEM</b>	<b>236</b>	<b>318</b>	<b>-26%</b>
Exceptional item, Net	-	-	-
<b>PBT FROM CONTINUING OPERATIONS</b>	<b>236</b>	<b>318</b>	<b>-26%</b>
Taxes	49	63	-22%
Taxes on exceptional item	-	22	-100%
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>187</b>	<b>234</b>	<b>-20%</b>
Minority interest	18	28	-35%
Minority interest on exceptional item	-	-	-
<b>NET PROFIT FOR THE PERIOD FROM CONTINUING OPERATIONS</b>	<b>169</b>	<b>206</b>	<b>-18%</b>
<b>LOSS FROM DISCONTINUING OPERATION</b>	<b>1</b>	<b>3</b>	<b>-75%</b>
<b>NET PROFIT FOR THE PERIOD</b>	<b>169</b>	<b>203</b>	<b>-17%</b>
<b>EPS Rs.</b>	<b>1.4</b>	<b>1.7</b>	
<b>NET PROFIT BEFORE EXCEPTIONAL ITEM AND DISCONTINUING OPERATION</b>			
	<b>169</b>	<b>228</b>	<b>-26%</b>
Loss from discontinuing operation	1	3	-75%
Exceptional item, net of taxes	-	(22)	-100%
<b>NET PROFIT FOR THE PERIOD</b>	<b>169</b>	<b>203</b>	<b>-17%</b>
<i># Licensing Income</i>	<i>11</i>	<i>9</i>	
<i>* Gross Research &amp; Development expenses</i>	<i>183</i>	<i>155</i>	

<b>BIOCON LIMITED (CONSOLIDATED)</b>			
<b>PROFIT &amp; LOSS STATEMENT</b>			
			(Rs. Crores)
Particulars	Q3' FY 21	Q2' FY 21	Variance %
<b>INCOME</b>			
Generics	561	599	-6%
Biosimilars	769	676	14%
Novel Biologics	-	-	-
Research services	585	520	12%
Inter-segment	(63)	(50)	27%
<b>Revenue from operations #</b>	<b>1,851</b>	<b>1,745</b>	<b>6%</b>
Other income	28	16	80%
<b>TOTAL REVENUE</b>	<b>1,879</b>	<b>1,760</b>	<b>7%</b>
<b>EXPENDITURE</b>			
Material & Power costs	632	601	5%
Staff costs	411	383	7%
Research & Development expenses*	171	148	15%
Other expenses	239	222	8%
<b>Manufacturing, staff &amp; other expenses</b>	<b>1,452</b>	<b>1,353</b>	<b>7%</b>
<b>EBITDA</b>	<b>427</b>	<b>407</b>	<b>5%</b>
Interest & Finance charges	5	7	-26%
Depreciation & Amortisation	186	178	5%
<b>PBT FROM CONTINUING OPERATIONS</b>	<b>236</b>	<b>223</b>	<b>6%</b>
Taxes	49	22	119%
Taxes on exceptional item	-	-	0%
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>187</b>	<b>200</b>	<b>-6%</b>
Minority interest	18	26	-31%
Minority interest on exceptional item	-	-	-
<b>NET PROFIT FOR THE PERIOD FROM CONTINUING OPERATIONS</b>	<b>169</b>	<b>174</b>	<b>-3%</b>
<b>LOSS FROM DISCONTINUING OPERATION</b>	<b>1</b>	<b>5</b>	<b>-84%</b>
<b>NET PROFIT FOR THE PERIOD</b>	<b>169</b>	<b>169</b>	<b>0%</b>
<b>EPS Rs.</b>	<b>1.4</b>	<b>1.4</b>	
<b>NET PROFIT BEFORE DISCONTINUING OPERATION</b>			
	<b>169</b>	<b>174</b>	<b>-3%</b>
Loss from discontinuing operation	1	5	-84%
<b>NET PROFIT FOR THE PERIOD</b>	<b>169</b>	<b>169</b>	<b>0%</b>
<i># Licensing Income</i>	<i>11</i>	<i>11</i>	
<i>* Gross Research &amp; Development expenses</i>	<i>183</i>	<i>165</i>	

<b>BIOCON LIMITED (CONSOLIDATED)</b>			
<b>PROFIT &amp; LOSS STATEMENT</b>			
			(Rs. Crores)
Particulars	9M FY 21	9M FY 20	Variance %
<b>INCOME</b>			
Generics	1,758	1,645	7%
Biosimilars	2,137	1,882	14%
Novel Biologics	-	-	-
Research services	1,526	1,405	9%
Inter-segment	(154)	(188)	-18%
<b>Revenue from operations #</b>	<b>5,267</b>	<b>4,743</b>	<b>11%</b>
Other income	56	98	-43%
<b>TOTAL REVENUE</b>	<b>5,323</b>	<b>4,841</b>	<b>10%</b>
<b>EXPENDITURE</b>			
Material & Power costs	1,835	1,636	12%
Staff costs	1,152	974	18%
Research & Development expenses*	426	314	35%
Other expenses	645	535	20%
<b>Manufacturing, staff &amp; other expenses</b>	<b>4,057</b>	<b>3,459</b>	<b>17%</b>
<b>EBITDA</b>	<b>1,266</b>	<b>1,383</b>	<b>-8%</b>
Interest & Finance charges	24	48	-51%
Depreciation & Amortisation	531	400	33%
<b>PBT BEFORE EXCEPTIONAL ITEM</b>	<b>711</b>	<b>935</b>	<b>-24%</b>
Exceptional item, Net	-	68	-
<b>PBT FROM CONTINUING OPERATIONS</b>	<b>711</b>	<b>1,002</b>	<b>-29%</b>
Taxes	152	205	-26%
Taxes on exceptional item	-	66	-100%
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>559</b>	<b>732</b>	<b>-24%</b>
Minority interest	63	73	-15%
Minority interest on exceptional item	-	14	-
<b>NET PROFIT FOR THE PERIOD FROM CONTINUING OPERATIONS</b>	<b>497</b>	<b>645</b>	<b>-23%</b>
<b>LOSS FROM DISCONTINUING OPERATION</b>	<b>9</b>	<b>21</b>	<b>-54%</b>
<b>NET PROFIT FOR THE PERIOD</b>	<b>487</b>	<b>625</b>	<b>-22%</b>
<b>EPS Rs.</b>	<b>4.1</b>	<b>5.2</b>	
<b>NET PROFIT BEFORE DISCONTINUING OPERATION</b>			
	<b>497</b>	<b>645</b>	<b>-23%</b>
Loss from discontinuing operation	9	21	-54%
Exceptional item, net of taxes	-	(12)	
<b>NET PROFIT FOR THE PERIOD</b>	<b>487</b>	<b>625</b>	<b>-22%</b>
# Licensing Income	32	23	
* Gross Research & Development expenses	491	388	

**BIOCON LIMITED (CONSOLIDATED)**  
**BALANCE SHEET**

(Rs Crores)

Particulars	December 31, 2020	March 31, 2020
<b>ASSETS</b>		
<b>Non-current assets</b>		
(a) Property, plant and equipment	5,258	5,393
(b) Capital work-in-progress	2,310	1,577
(c) Goodwill	26	26
(d) Other intangible assets	632	423
(e) Intangible assets under development	530	620
(f) Right-of-use assets	156	128
(g) Investment in associates and a joint venture	-	14
(h) Financial assets		
Investments	114	94
Derivative assets	43	26
Other financial assets	61	56
(i) Income tax asset, net	306	242
(j) Deferred tax asset, net	357	368
(k) Other non-current assets	161	151
<b>Non-current assets</b>	<b>9,953</b>	<b>9,119</b>
<b>Current assets</b>		
(a) Inventories	1,786	1,436
(b) Financial assets		
Investments	1,472	858
Trade receivables	1,199	1,224
Cash and cash equivalents	1,262	910
Other bank balances	686	89
Derivative assets	71	19
Other financial assets	828	450
(c) Other current assets	365	340
(c) Assets held for sale	65	-
<b>Current assets</b>	<b>7,734</b>	<b>5,325</b>
<b>TOTAL - ASSETS</b>	<b>17,687</b>	<b>14,444</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity share capital	600	600
(b) Other equity	6,701	6,106
<b>Equity attributable to owners of the Company</b>	<b>7,301</b>	<b>6,706</b>
Non-controlling interests	804	677
<b>Total Equity</b>	<b>8,105</b>	<b>7,383</b>
<b>Non-current liabilities</b>		
(a) Financial liabilities		
Borrowings	3,306	1,222
Lease liabilities	115	83
Derivative liabilities	90	146
Other financial liabilities	942	536
(b) Provisions	103	86
(c) Deferred tax liability, net	32	30
(d) Other non-current liabilities	1,006	949
<b>Non-current liabilities</b>	<b>5,594</b>	<b>3,053</b>
<b>Current liabilities</b>		
(a) Financial liabilities		
Borrowings	661	668
Lease liabilities	11	7
Trade payables	1,534	1,325
Derivative liabilities	39	72
Other financial liabilities	1,140	1,208
(b) Provisions	122	103
(c) Income tax liability, net	194	128
(d) Other current liabilities	234	498
(e) Liabilities classified as held for sale	53	-
<b>Current liabilities</b>	<b>3,988</b>	<b>4,008</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>17,687</b>	<b>14,444</b>